HEALTH OF WOMAN. 2020.2(148): 7–14; doi 10.15574/HW.2020.148.7
Hychka N. M., Shcherba O. A., Lastovetska L. D.
Bogomolets National Medical University, Kiev

Inflammatory diseases of the pelvic organs (PID) occupy the first place in the structure of gynecological morbidity and are one of the causes of dysfunction of not only the reproductive organs but also various systems of the female body, infertility, and a decrease in the quality of life. The PID includes inflammatory processes of the uterus, fallopian tubes, ovaries and pelvic peritoneum.
The article presents modern views on etiological factors, stages of development of endogenous infection and its clinical manifestations. The mechanisms of endocrine and immune regulation of the vaginal microbiocenosis, as well as the relationship of endogenous microflora and pathogens of exogenous genital infections, are examined. Diagnostic approaches and principles of treatment of PID are presented, taking into account the severity of the infectious process.
Key words: рelvic inflammatory diseases, salpingitis, endometritis, microbiocenosis, sexual exinfection, diagnosis, treatment principles.

REFERENCES

1. Ankirskaya AS, Muravyova VV. 2000. The species composition and some biological properties of lactobacilli in various conditions of the vaginal microecology. Obstetrician. and gynecol. 3:26–28.

2. Benyuk VA, Lastovetskaya LD, Usevich IA, Shcherba EA, Samsonova SS. 2008. Modern approaches to the diagnosis and treatment of inflammatory diseases of the uterus. Women's Health 2(34):67-70.

3. Bukharin OV, Valyshev AV, Gilmutdinova FG et al. 2006. Ecology of human microorganisms. Ekaterinburg: Ural Branch of the Russian Academy of Sciences.

4. Krasnopolsky VI et al. 2004. The effect of infections on the reproductive system of women. Ros. Vestn. obstetrician.- gynecol. 4;5:26-30.

5. Serov VN et al. 2008. Gynecology: A guide for doctors. Ed. Serova VN, Kira EF. M, Litterra:840.

6. Gritsenko VA, Ivanov YuB. 2009. Role of persistent properties of microorganisms in the pathogenesis of endogenous bacterial infections. Vestn. Ural. honey. Acad. science. 2:35–39.

7. Duda VI. 2008. Gynecology. 2nd ed. erased. Minsk, Harvest: 896, 199-202.

8. Ed. Vorobyev AA et al. 2006. Immunology and allergology (color atlas): Textbook. The allowance.M,Practical. honey. Gynecology: National Hand. / Ed. Kulakova VI, Manukhin IB, Savelyeva GM. M, GEOTARMEDIA. 2007.

9. Ed. Prilepskaya VN. Sexually transmitted infections: Clinical lectures. M, GEOTAR-Media. 2014.

10. Katkova IP. 2002. Reproductive health of Russians. Population. 4:39–42.

11. Ed. Serova VN, Sukhikh GT. Clinical recommendations. Obstetrics and gynecology (4th ed.). M, GEOTAR-Media. 2014.

12. Kozlova VI, Puchner AF. 1997. Viral, chlamydial and mycoplasma diseases of the genitals. M, Filin:536.

13. Kornatska AG, Vovk IB, Chubei GV. 2012. Zapalnnye seizure of the pelvic organs, due to infections, which are transmitted by the style of the hat. Health’s Ukraine 4:38-39.

14. Korshunov NM, Volodin NN, Efimov BA et al. 1999. Microecology of the vagina. Correction of microflora in vaginal dysbiosis: Textbook. allowance. M, VUNMTS Ministry of Health of the Russian Federation.

15. Kosey NV. 2013. Modern principles for the treatment of inflammatory diseases of the female genital organs. Reproductive Endocrinology 1(9):78-85. https://doi.org/10.18370/2309-4117.2013.9.78-85

16. Kocherovets VI, Bunyatyan ND. 2011. Normal microflora of the female genitourinary tract and preparations for its correction: Textbook. allowance. M, ACTEON.

17. Kulakov VI, Prilepskaya VN, Radzinsky VE. 2006. A guide to outpatient care in obstetrics and gynecology. M, GEOTAR-Media.

18. Lebedeva OP, Kalutsky PV, Pakhomov SP et al. 2009. Congenital immunity of the female genital tract and its hormonal regulation (mini-review). Scientific. Vedomosti Belgorod. state University (Medicine, pharmacy) 12(67):25–31.

19. Medvedev BI, Dolgushina VF. 1993. Local anti-infectious immunity of the female reproductive system. Obstetrician. and gynecol. 4:7–9.

20. Medvedev BI, Kazachkova EA, Cossacks EL. 2000. Features of local immunity in women with chronic inflammatory diseases of the pelvic organs associated with chlamydia. Journal. microbiol., epidemiol. and immunobiol. 2:89–92.

21. Mirsky VYe, Rischuk SV. 2012. Diseases of the reproductive system in children and adolescents (andrological aspects): Hands. for doctors. SPb, SpetsLit.

22. Mikhalevich SI. 2002. Overcoming infertility: diagnosis, clinic. treatment: textbook. allowance for students of the specialty «Medical and preventive care» honey. universities. Minsk: Belaruskaya Navuka: 191, 32.

23. Naumov IA, Tishchenko EM. 2012. Inflammatory diseases of the female genital organs: the organization of medical care for patients in 1944-1994 (on the example of the Grodno region): monograph. Grodno, State State Medical University 248.

24. Prilepskaya VN. 2002. Infections in gynecology. Features of infectious processes of the lower genital tract. Possibilities of drug therapy for local use. Gynecol. 2;2:17–19.

25. Prozorovsky SV, Rakovskaya IV, Vulfovich YuV. 1995. Medical mycoplasmology. M, Medicine:288. Balabanov DN. 2009. Antigenemia in urogenital mycoplasma infections: Abstract. dis. Cand. honey. sciences. M.

26. Rischuk SV, Dushenkova TA. 2013. Optimization of the diagnosis of reproductive significant infections in couples. Terra Medica. 4:20–33.

27. Rischuk SV. 2013. Sexual infections as the main cause of the deterioration in the reproductive health of couples. Terra Medica. 3:5–11.

28. Rischuk SV. 2015. Infectious and inflammatory diseases of the female genital organs: etiology, fundamental approaches to diagnosis and treatment. TERRA MEDICA. 4:4-15:4.

29. Rischuk SV, Malisheva AA. 2014. Endogenous vaginal microbiota and its violation. Diagnosis and principles of correction. TERRA MEDICA. 2:9-21.

30. Guide to Gynecology. Ed. RAMS prof. E.K. Haylamazyan. M, MEDpress-inform. 2012.

31. Sepsis at the beginning of the 21st century. Classification, clinical diagnostic concept and treatment. Pathological and anatomical diagnosis: Practical. hands. Ed. Saveliev VS, Gelfand BR. 2006. M, Litterra.

32. Tatarchuk TF, Kosey NV. 2012. Empirical therapy of vaginal infections. – Institute of Pediatrics, Obstetrics and Gynecology of Ukraine.

33. Utkin EV, Kulavsky VA. Modern features of the clinical course of inflammatory diseases of the uterine appendages. Actual issues of obstetrics and gynecology: Sat. scientific tr interregional scientific – prakt. Conf., Krasnoyarsk, March 20-21, 2008. Ministry of Health and Social Development of the Russian Federation. Feder., Ministry of Health and Social Development of the Krasnoyarsk Territory, Ros. assoc. obstetrician-gynecol., Krasnoyarsk. Gos. honey. un-t them. prof. V.F. War-Yasenetsky, Rec .: Serov VN et al. 2008. Krasnoyarsk: Krasnoyarsk State Medical University: 146–149.

34. Tselkovich LS, Rogacheva VS. 1998. Reproductive function in women living under the influence of adverse environmental factors. Obstetrician. and gynecol. 2:24–27.

35. Shenderov BA. 1998. Medical microbial ecology and functional nutrition. T. I. Microflora of humans and animals and its functions. M, Grant.

36. Shcherba OA, Lastovetska LD, Polovinka VO, Shako VA. 2019. Clinical aspects of asocial candidiasis – herpetic vulvovaginitis. Women's Health 7(143):85-89.

37. Yaglov VV. 2001. Inflammatory diseases of the pelvic organs. Gynecol. 1;3:40–43.

38. Hillier SL et al. 1988. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N. Engl. J. Med. 319:972–978. https://doi.org/10.1056/NEJM198810133191503; PMid:3262199

39. Agarwal AK, Wilmer WA, Bay WH. 2002. Pneumococcal and gonococcal peritonitis due to vaginitis. Perit. Dial. Int. 22;6:731–732. https://doi.org/10.1177/089686080202200618

40. Arntzen КJ, Kjollesdal AM, Halgunset J. 1998. TNF, IL-1, IL-6, IL-8 and soluble TNF receptors in relation to chorioamnionitis and premature labor. J. Perinat. Med. 26:17–26. https://doi.org/10.1515/jpme.1998.26.1.17; PMid:9595363

41. Deguchi T et al. 2004. Association of Ureaplasma urealyticum (biovar 2) with nongonococcal urethritis. Sex. Transm. Dis. 31:192–195. https://doi.org/10.1097/01.OLQ.0000114653.26951.71; PMid:15076934

42. Berman JM, Harrison BV. 1987. Low birth weights, prematurity and endometritis association with prenatal infection. JAMA. 257;4:1189–1194. https://doi.org/10.1001/jama.257.9.1189; PMid:3806917

43. Bevan CD, Ridgway GL, Rothermel CD. 2003. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J Int Med Res 31:45–54. https://doi.org/10.1177/147323000303100108; PMid:12635534

44. Boothby M, Page J, Pryor R et al. 2010. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 21:195–7. https://doi.org/10.1258/ijsa.2009.009374; PMid:20215625

45. Boris S, Barbes C. 2000. Role played by lactobacilli in controlling the population of vaginal pathogens. Micr. Infect. 2;5:543–546. https://doi.org/10.1016/S1286-4579(00)00313-0

46. Burnett AM, Anderson CP, Zwank MD. 2012. Laboratory-confirmed gonorrhea and/or chlamydia rates in clinically diagnosed pelvic inflammatory disease and cervicitis. Am J Emerg Med 30:1114–7. https://doi.org/10.1016/j.ajem.2011.07.014; PMid:22030186

47. Gibbs RS. 1995. A revive of premature birth and subclinical infection. Clin. Perinatal. 22;2: 281–342.  Jennings RT, Baker ES. 2000. Gynecological and reproductive issues for women in space: a review. Obstet. Gynecol. Surv. 55;2: 109–116. https://doi.org/10.1097/00006254-200002000-00025; PMid:10674254

48. Golden MR, Whittington WL, Handsfield HH et al. 2005. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 352:676–85. https://doi.org/10.1056/NEJMoa041681; PMid:15716561

49. Gray Y, Libbey NP. 2001. Xanthogranulomatous salpingitis and oophoritis: a case report and review of the literature. Arch. Pathol. Lab. Med. 125;2:260–263.

50. Grenabo L, Hedelin H, Pettersson S. 1988. Urinary infection stones caused by Ureaplasma urealyticum: a review. Scand. J. Infect. Dis. Suppl. 53:46–49.

51. Grimes DA. 2000. Intrauterine device and upper-genital-tract infection. Lancet 356:1013–9. https://doi.org/10.1016/S0140-6736(00)02699-4

52. Haefner HK. 1999. Current evaluation and management of vulvovaginitis. Clin. Obstet. Gynecol. 42;2:184–195. Sobel JD. 1997. Vaginitis. N. Engl. J. Med. 337: 1896–1903. https://doi.org/10.1097/00003081-199906000-00004; PMid:10370840

53. Heystek M, Ross JD. 2009. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 20:690–5. https://doi.org/10.1258/ijsa.2008.008495; PMid:19815913

54. Hosenfeld CB, Workowski KA, Berman S et al. 2009. Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 36:478–89. https://doi.org/10.1097/OLQ.0b013e3181a2a933; PMid:19617871

55. Jares EJ, Sanchez-Borges M, Cardona-Villa R et al. 2014. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol 113:282–9. https://doi.org/10.1016/j.anai.2014.06.019; PMid:25065979

56. Jennings RT, Baker ES. 2000. Gynecological and reproductive issues for women in space: a review. Obstet. Gynecol. Surv. 55;2:109–116. https://doi.org/10.1097/00006254-200002000-00025; PMid:10674254

57. Judlin P, Liao Q, Liu Z et al. 2010. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. Br J Obstet Gynaecol 117:1475–84. https://doi.org/10.1111/j.1471-0528.2010.02687.x; PMid:20716255

58. Kohl KS, Markowitz LE, Koumans EH. 2003. Developments in the screening for Chlamydia trachomatis: a review. Obstet Gynecol Clin North Am. 30(4):637-58. https://doi.org/10.1016/S0889-8545(03)00076-7

59. Lindbohm ML. 1999. Women's reproductive health: some recent developments in occupational epidemiology. Am. J. Ind. Med. 36;1:18–24. https://doi.org/10.1002/(SICI)1097-0274(199907)36:1<18::AID-AJIM3>3.0.CO;2-N

60. Lyon A. 2000. Chronic lung disease of prematurity. The role of intrauterine infection. Eur. J. Pediatr. 159:798–802. https://doi.org/10.1007/s004310000587; PMid:11079191

61. McGregor JA, Crombleholme WR, Newton E et al. 1994. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 83:998–1004. https://doi.org/10.1097/00006250-199406000-00020; PMid:8190448

62. Ness RB, Hillier SL, Kip KE et al. 2004. Bacterial vaginosis and risk of pelvic inflammatory disease. Obstet Gynecol 104:761–9. https://doi.org/10.1097/01.AOG.0000139512.37582.17; PMid:15458899

63. Ness RB, Kip KE, Hillier SL et al. 2005. A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol 162:585–90. https://doi.org/10.1093/aje/kwi243; PMid:16093289

64. Ness RB, Soper DE, Holley RL et al. 2002. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 186:929–37. https://doi.org/10.1067/mob.2002.121625; PMid:12015517

65. Ness RB, Soper DE, Holley RL et al. 2002. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) randomized trial. Am J Obstet Gynecol 186:929–37. https://doi.org/10.1067/mob.2002.121625; PMid:12015517

66. Ochiel DO, Fahey JV, Ghosh M et al. 2008. Innate immunity in the female reproductive tract: role of sex hormones in regulating uterine epithelial cell protection against pathogens. Curr. Womens Hlth Rev. 4;2:102–117. https://doi.org/10.2174/157340408784246395; PMid:19644567 PMCid:PMC2717724

67. Prasertsawat PO, Jetsawangsri T. 1992. Split-dose metronidazole or single-dose tinidazole for the treatment of vaginal trichomoniasis. Sex Transm Dis 19:295–7. https://doi.org/10.1097/00007435-199209000-00011; PMid:1411848

68. Bonnin F et al. 1995. Prospective study of neonatal genital mycoplasma colonization and infection. Arch. Pediatr. 2:636–642. https://doi.org/10.1016/0929-693X(96)81217-6

69. Saji F. 1998. Immunological aspects of chorionamnionitis. Am. J. Reproduct. Immunol. 40:254.

70. Savaris RF, Teixeira LM, Torres TG et al. 2007. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol 110:53–60. https://doi.org/10.1097/01.AOG.0000268801.90261.27; PMid:17601896

71. Schillinger JA, Kissinger P, Calvet H et al. 2003. Patient-delivered partner treatment with azithromycin to prevent repeated Chlamydia trachomatis infection among women – a randomized, controlled trial. Sex Transm Dis 30:49–56. https://doi.org/10.1097/00007435-200301000-00011; PMid:12514443

72. Smith KJ, Ness RB, Wiesenfeld HC et al. 2007. Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sex Transm Dis 34:960–6. https://doi.org/10.1097/01.olq.0000225321.61049.13

73. Soroka AE et al. 2001. Genetic heterogeneity of Mycoplasma hominis clinical isolates detected during observation patients with recurrent urogenital inflammation. Bull. Exp. Biol. Med. 132;1:663–665. https://doi.org/10.1023/A:1012528311987; PMid:11687848

74. Sweet RL. 2011. Treatment of acute pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011:561909.

75. Tepper NK, Steenland MW, Gaffield ME et al. 2013. Retention of intrauterine devices in women who acquire pelvic inflammatory disease: a systematic review. Contraception 87:655–60. https://doi.org/10.1016/j.contraception.2012.08.011; PMid:23040135

76. Viberga I, Odlind V, Lazdane G et al. 2005. Microbiology profile in women with pelvic inflammatory disease in relation to IUD use. Infect Dis Obstet Gynecol 13:183–90. https://doi.org/10.1155/2005/376830; PMid:16338777 PMCid:PMC1784576

77. WHO. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus. Ed. M. Unemo et al. Printed by the Document Production Services, Geneva, Switzerland: 228. 2013.

78. Wiesenfeld HC, Hillier SL, Meyn L, et al. Mycoplasma genitalium – is it a pathogen in acute pelvic inflammatory disease (PID)? STI & AIDS World Congress 2013 (Joint Meeting of the 20th ISSTDR and 14^th IUSTI Meeting). 2013, July 14-27. Vienna, Austria.

79. Wiesenfeld HC, Hillier SL, Meyn LA et al. 2012. Subclinical pelvic inflammatory disease and infertility. Obstet Gynecol 120:37–43. https://doi.org/10.1097/AOG.0b013e31825a6bc9; PMid:22678036

80. Wiesenfeld HC, Sweet RL, Ness RB et al. 2005. Comparison of acute and subclinical pelvic inflammatory disease. Sex Transm Dis 32:400–5. https://doi.org/10.1097/01.olq.0000154508.26532.6a; PMid:15976596

81. Workowski KA, Bolan GA. 2015. Sexually Transmitted Diseases Treatment Guidelines. MMWR Recomm Rep. 64(RR-03):1-137. Available at: https://www.ncbi.nlm.nih.gov/ pubmed/26042815.   с.78.